Abstract
: Objectives: The objective of this study was to compare clinical outcomes of Nonsteroidal anti-inflammatory drugs as monotherapy and combinational therapy with glucosamine in osteoarthritis patients. Methods: A randomized prospective observational study was conducted between December 2018 and June 2019 at M. M. Institute of Medical Science and Research. Total 360 patients were recruited and were divided into four different groups. Patients received selective cyclooxegenase-2 inhibitor with and without glucosamine sulphate and non-selective cyclooxegenase-2 inhibitor with and without glucosamine sulphate. The primary outcomes were measured by liquesce index score and visual analogue scale at 2nd and 4th week. Results: Bodyweight and the age were found statistical significant among different groups. Both the combination treatment groups were statistical significant potent than individual treatment group after the four weeks of treatment. Statistical significant results were found in both liquesce index (LI) and Visual Analogues Score (VAS). Conclusion: Marked improvement was observed in both the scores (Lequesne index and Visual Analogues) after four weeks of treatment and it would be better therapy in both the combination with Glucosamine than individual for osteoarthritis patient.Key words: Cyclooxegenase-2 inhibitor, Follow up treatment, Glucosamine sulphate, Inflammation, Rheumatology, Visual Analogues Score.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
